<DOC>
	<DOCNO>NCT00313053</DOCNO>
	<brief_summary>This phase I trial patient relapse refractory leukemia human monoclonal antibody kill B cell acute lymphoblastic leukemia . The trial study safety , pharmacokinetics , anti-tumor activity antibody give single agent vincristine .</brief_summary>
	<brief_title>Study mAb 216 With Chemotherapy Treatment Pediatric Relapsed Refractory B-progenitor Acute Lymphoblastic Leukemia</brief_title>
	<detailed_description />
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<mesh_term>Vincristine</mesh_term>
	<criteria>Patients must &gt; 12 month time study entry . Patients must histologic verification Blineage ALL bone marrow relapse refractory disease unresponsive traditional chemotherapy . For patient WITHOUT prior allogeneic bone marrow transplant ( BMT ) : Second subsequent bone marrow relapse Primary refractory marrow disease M3 marrow ( &gt; 25 % blast ) For patient WITH prior allogeneic BMT : First subsequent bone marrow relapse postBMT M3 marrow M2 ( &gt; 5 % &lt; 25 % blast ) cytogenetic variable number tandem repeat ( VNTR ) confirmation Confirmation antibody reactivity Patient 's leukemic blast ( peripheral blood marrow ) must document bind mAb 216 vitro ( Teng lab ) . Patient 's red blood cell ( RBC ) document NOT express fetal `` '' antigen RBC show NOT bind mAb 216 vitro ( Teng lab ) Patient must eligible therapy high priority Performance level Karnofsky 50 % patient &gt; 10 year age Lansky &gt; = 50 patient &lt; = 10 year age . Life expectancy must least 8 week . Patients must fully recover acute toxic effect prior chemotherapy , immunotherapy , radiotherapy prior enter study : Myelosuppressive chemotherapy : must receive within 2 week entry onto study . Biologic : least 7 day since completion therapy biologic agent . No hematologic criterion white blood cell ( WBC ) , hemoglobin ( Hgb ) , platelets Patients thrombocytopenia responsive platelet transfusion must uncontrolled bleeding . Adequate renal function define : serum creatinine less equal 1.5 x normal age Adequate liver function define : total bilirubin &lt; = 1.5 x upper limit normal ( ULN ) age , SGPT ( ALT ) &lt; = 5 x upper limit normal ( ULN ) age Adequate cardiac function define : shortening fraction &gt; = 27 % echocardiogram , ejection fraction &gt; = 50 % gate radionuclide study . All patient and/or parent legal guardian must sign write informed consent/assent . All Institutional Review Board ( IRB ) Food Drug Administration ( FDA ) requirement human study must meet . Central nervous system ( CNS ) 3 refractory CNS leukemia Isolated extramedullary relapse Uncontrolled infection Lack mAb 216 binding patient 's leukemic blast vitro Binding mAb 216 '' '' antigen patient 's erythrocyte Prior treatment rituximab</criteria>
	<gender>All</gender>
	<minimum_age>12 Months</minimum_age>
	<maximum_age>18 Years</maximum_age>
	<verification_date>November 2012</verification_date>
</DOC>